{"id":485431,"date":"2020-05-20T07:24:02","date_gmt":"2020-05-20T07:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=485431"},"modified":"2020-05-20T07:24:02","modified_gmt":"2020-05-20T07:24:02","slug":"openangle-glaucoma-market-size-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/openangle-glaucoma-market-size-epidemiology-and-market-forecast2030_485431.html","title":{"rendered":"Open-Angle Glaucoma Market Size, Epidemiology and Market Forecast-2030"},"content":{"rendered":"
\"Open-Angle<\/a><\/p>\n
\n
DelveInsight <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s Open-angle glaucoma (OAG) \u2013 Market Insights, Epidemiology, and Market Forecast\u20142030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/div>\n

Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

(Albany, US) <\/span>DelveInsight launched a new report on Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

Some of the key facts of the report<\/span>
1. The total Glaucoma prevalent population was 9,819,080 in the 7MM in 2017.<\/span>
2. The total diagnosed prevalent population of Open-Angle Glaucoma (OAG) in the 7MM was 8,823,960 in 2017.<\/span>
3. The prevalent cases of OAG in the United States in 2017 was 2,749,378.<\/span>
4. The most prevalent age-group for OAG in the United States in 2017 was 70–79.<\/span><\/p>\n

Key benefits of the report<\/span>
1. Open-Angle Glaucoma market report covers a descriptive overview and comprehensive insight of the Open-Angle Glaucoma epidemiology and Open-Angle Glaucoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Open-Angle Glaucoma market report provides insights into the current and emerging therapies.<\/span>
3. Open-Angle Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Open-Angle Glaucoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Open-Angle Glaucoma market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

\"\"<\/a><\/p>\n

“Open-Angle Glaucoma Market Size was USD 3,316.71 million in the 7MM in 2017”.<\/span><\/p>\n

The main goal of glaucoma treatment is to increase the quality of life through the reduction of intraocular pressure (IOP) to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable and affordable.<\/span><\/p>\n

However, the medical treatment of Glaucoma has associated side effects, complications, and costs. There are several risk factors like age more than 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.<\/span><\/p>\n

Management of the disease aims at lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogues, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors.<\/span><\/p>\n

Prostaglandin analogues are the first treatment choice for many glaucoma patients. Before the entry of prostaglandins in the market, Beta-blockers were quite famous and popular for the management of Glaucoma. Ocular hypotensive agents other than beta-blockers, such as the alpha2 agonist brimonidine, maybe a more appropriate first-line therapy for ocular hypertension and glaucoma patients concurrently taking systemic beta-blockers.<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact Open-Angle Glaucoma treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span>
– Bimatoprost SR<\/span>
– PDP-716<\/span>
– PRO-122<\/span>
– DE-130A<\/span>
– CKD-351<\/span>
– NCX 470<\/span>
– Bamosiran<\/span>
– ENV515<\/span>
– Nyxol<\/span>
– POLAT-001<\/span>
– Trabodenoson<\/span>
– OTX-TP<\/span>
And many others<\/span><\/p>\n

The key players in Open-Angle Glaucoma market are:<\/span>
– Allergan<\/span>
– Sun Pharma Advanced Research Company Limited (SPARC)<\/span>
– Laboratorios Sophia S.A de C.V.<\/span>
– Santen Pharmaceutical<\/span>
– Chong Kun Dang Pharmaceutical<\/span>
– Nicox Ophthalmics<\/span>
– Sylentis<\/span>
– Envisia Therapeutics<\/span>
– Ocuphire Pharma<\/span>
– Peregrine Ophthalmic<\/span>
– Inotek Pharmaceuticals<\/span>
– Ocular Therapeutix<\/span>
And many others<\/span><\/p>\n

Table of contents<\/span>
1. Key Insights<\/span><\/p>\n

2. Executive Summary of Open-Angle Glaucoma<\/span><\/p>\n

3. Open-Angle Glaucoma Market Overview at a Glance<\/span><\/p>\n

4. Open-Angle Glaucoma Disease Background and Overview<\/span><\/p>\n

5. Case Reports<\/span><\/p>\n

6. Open-Angle Glaucoma Epidemiology and Patient Population<\/span><\/p>\n

7. United States Epidemiology<\/span><\/p>\n

8. EU5 Epidemiology<\/span><\/p>\n

8.1. Germany Epidemiology<\/span><\/p>\n

8.2. France Epidemiology<\/span><\/p>\n

8.3. Italy Epidemiology<\/span><\/p>\n

8.4. Spain Epidemiology<\/span><\/p>\n

8.5. United Kingdom Epidemiology<\/span><\/p>\n

9. Japan Epidemiology<\/span><\/p>\n

10. Open-Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

11. Unmet Needs<\/span><\/p>\n

12. Open-Angle Glaucoma Marketed Products<\/span><\/p>\n

12.1. Marketed Products And Their Relative Therapeutic Classes<\/span><\/p>\n

12.2. ROCKLATAN: Aerie Pharmaceuticals<\/span><\/p>\n

12.3. Rhopressa: Aerie Pharmaceuticals<\/span><\/p>\n

12.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited<\/span><\/p>\n

12.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical\/Ube Industries<\/span><\/p>\n

12.6. VYZULTA: Bausch and Lomb<\/span><\/p>\n

12.7. TAPCOM\/ DE-111 (Tafluprost\/timolol maleate): Santen Pharmaceutical Co., Ltd.<\/span><\/p>\n

12.8. GLANATEC: D.Western Therapeutics Institute (DWTI)\/Kowa LTD.<\/span><\/p>\n

12.9. Simbrinza (brinzolamide\/brimonidine tartrate ophthalmic suspension) 1%\/0.2%: Alcon Research<\/span><\/p>\n

12.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.<\/span><\/p>\n

12.11. DuoTrav PQ (travoprost\/timolol): Novartis\/Alcon Research<\/span><\/p>\n

12.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company<\/span><\/p>\n

12.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan<\/span><\/p>\n

13. Open-Angle Glaucoma Emerging Therapies<\/span><\/p>\n

13.1. Key Cross Competition<\/span><\/p>\n

13.2. Bimatoprost SR (Sustained-Release): Allergan<\/span>
13.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)<\/span><\/p>\n

13.4. PRO-122: Laboratorios Sophia S.A de C.V.<\/span><\/p>\n

13.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company<\/span><\/p>\n

13.6. DE-130A (latanoprost): Santen Pharmaceutical<\/span><\/p>\n

13.7. CKD-351: Chong Kun Dang Pharmaceutical<\/span><\/p>\n

13.8. Sepetaprost (DE-126\/ONO-9054): Santen Inc.\/Ono Pharmaceutical<\/span><\/p>\n

13.9. NCX 470: Nicox Ophthalmics<\/span><\/p>\n

13.10. Bamosiran (SYL040012): Sylentis<\/span><\/p>\n

13.11. ENV515 (Travoprost XR): Envisia Therapeutics<\/span><\/p>\n

13.12. Nyxol (Phentolamine Mesylate): Ocuphire Pharma<\/span><\/p>\n

13.13. POLAT-001: Peregrine Ophthalmic<\/span><\/p>\n

13.14. Failed Therapies<\/span><\/p>\n

13.15. Trabodenoson: Inotek Pharmaceuticals<\/span><\/p>\n

13.16. OTX-TP (Travoprost): Ocular Therapeutix<\/span><\/p>\n

14. Open-Angle Glaucoma 7MM Market Analysis<\/span><\/p>\n

15. United States: Market Outlook<\/span><\/p>\n

15.1. United States Market Size<\/span><\/p>\n

16. EU-5 countries: Market Outlook<\/span><\/p>\n

16.1. Germany Market Size<\/span><\/p>\n

16.2. France Market Size<\/span><\/p>\n

16.3. Italy Market Size<\/span><\/p>\n

16.4. Spain Market Size<\/span><\/p>\n

16.5. United Kingdom Market Size<\/span><\/p>\n

17. Japan Market Outlook<\/span><\/p>\n

18. Access and Reimbursement Overview of Open Angle Glaucoma<\/span><\/p>\n

19. Market Drivers<\/span><\/p>\n

20. Market Barriers<\/span><\/p>\n

21. SWOT Analysis<\/span><\/p>\n

22. Appendix<\/span><\/p>\n

23. DelveInsight Capabilities<\/span><\/p>\n

24. Disclaimer<\/span><\/p>\n

25. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Contact us:<\/span>
info@delveinsight.com<\/span>
+919650213330<\/span>
SOURCE DelveInsight<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight\u2019s Open-angle glaucoma (OAG) \u2013 Market Insights, Epidemiology, and Market Forecast\u20142030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-485431","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/485431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=485431"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/485431\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=485431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=485431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=485431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}